Drug Profile
Escherichia coli M17
Alternative Names: E. coli M17; ProbactrixLatest Information Update: 05 Feb 2015
Price :
$50
*
At a glance
- Originator The BioBalance Corporation
- Class Irritable bowel syndrome therapies; Probiotics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Coeliac disease; Gastro-oesophageal reflux; Irritable bowel syndrome
Most Recent Events
- 05 Feb 2015 Discontinued - Clinical-Phase-Unknown for Coeliac disease in Israel (PO)
- 05 Feb 2015 Discontinued - Phase-II for Irritable bowel syndrome in USA (PO)
- 05 Feb 2015 Discontinued - Phase III for Gastro-oesophageal reflux in USA (PO)